Investigational drug · Phase 2
DL001Z
Also called: F2G22B, F2H23H, F2H23G
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Influenza, Human.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
2
Any phase or sponsor naming "DL001Z"
First trial start
2024
May 23, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DL001Z", any sponsor or status.
Conditions studied
As listed on its trial records.
- Influenza, Human
Approved drugs for the same conditions: Influenza · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "DL001Z" as an intervention, largest first.
- A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older AdultsPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT05823974 · 1,275 participants · Start Apr 27, 2023 · Primary completion Jul 2, 2024
Drug: F2C22C/DL001Z; F2B22A/DL001Z and 14 more · For: Influenza, Human
Sites: Hialeah, Florida; Miami, Florida; Chicago, Illinois · 41 sites in all
- A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older AdultsPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT06431607 · 845 participants · Start May 23, 2024 · Primary completion Dec 27, 2024
Drug: F2G22B/DL001Z; F2H23D/DL001Z-NH and 5 more · For: Influenza, Human
Sites: Hialeah, Florida; Miami, Florida; Chicago, Illinois · 18 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Influenza, Human
- GP681Phase 32 trials
Jiangxi Qingfeng Pharmaceutical Co. Ltd. · Influenza, Human, Influenza
- GP681 SimulantPhase 32 trials
Jiangxi Qingfeng Pharmaceutical Co. Ltd. · Influenza, Human, Influenza
- Flu mRNAGSK6479720A, GSK6498032APhase 22 trials
GSK · Influenza, Human
- ARCT-2304Phase 21 trial
Arcturus Therapeutics, Inc. · Influenza, Human
- DL001Z-NHF2H23D, F2H23BPhase 21 trial
GSK · Influenza, Human
- GSK5800544APhase 21 trial
GSK · Influenza, Human
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.